10-Q · May 7, 2026
Amrize Ltd (AMRZ) reported Q1 2026 with revenue of $2.18 billion, reflecting a 4.7% increase from $2.08 billion year-over-year. However, net loss widened to $118 million compared to $87 million in the prior year. The…
Earnings analysis · 10-Q
AMRZ earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
Amrize's Q2 2026 results showed a substantial sequential recovery, with revenue of $3.494 billion and diluted EPS of $0.88 versus $2.18 billion and a $0.21 loss in Q1 2026. Revenue and EPS also improved versus Q2 2025,…
Read full summary
Amrize's Q2 2026 results showed a substantial sequential recovery, with revenue of $3.494 billion and diluted EPS of $0.88 versus $2.18 billion and a $0.21 loss in Q1 2026. Revenue and EPS also improved versus Q2 2025, although the supplied earnings data shows EPS was below the $0.99 consensus estimate. The filing continues to identify ineffective disclosure controls and an unresolved material weakness as significant governance and reporting risks, while providing no quantitative guidance.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $0.88
What stood out
-
Revenue rebounded strongly
Revenue was $3.494 billion, up approximately 60.3% from $2.18 billion in Q1 2026 and 8.5% from $3.22 billion in Q2 2025.
-
EPS recovered year over year
Diluted EPS was $0.88 versus a loss of $0.21 in Q1 2026 and $0.78 in Q2 2025, indicating a $1.09 sequential improvement and $0.10 year-over-year increase.
-
Share repurchases began
Amrize repurchased 3,759,896 shares during Q2 2026. The program had a $1.0 billion authorization and 15,059,621 shares remaining as of June 30, 2026.
-
Market risk profile unchanged
Management stated that there were no material changes to market risks from those disclosed in the 2025 Form 10-K for the six months ended June 30, 2026.
What to watch
-
Material weakness remains unresolved
Disclosure controls were not effective as of June 30, 2026 because of a previously reported material weakness related to insufficient accounting and supervisory personnel with appropriate U.S. GAAP technical experience and training.
-
Remediation remains incomplete
The company said the material weakness will not be considered remediated until enhanced controls operate for a sufficient period and testing concludes they are effective; the filing provides no completed remediation date.
-
No material risk-factor improvement
The filing states there were no material changes to risk factors disclosed in the 2025 Form 10-K, limiting evidence of any reduction in the company's existing risk profile.
Management's outlook
The supplied 10-Q text does not provide quantitative revenue or EPS guidance. Recent news references a guidance cut, but that information is outside the filing text.
Earlier filings 3
10-K · February 18, 2026
Amrize completed its June 23, 2025 spin-off from Holcim and operates as a North American building-solutions company organized into two reportable segments (Building Materials and Building Envelope). The filing…
10-Q · August 7, 2025
Amrize Ltd's Q2 2025 results reflect a decline in revenue and earnings compared to the previous quarter and prior year, attributing challenges to operational adjustments following its separation from Holcim. The company…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.